p38α mitogen-activated protein kinase inhibitors, a patent review (2005-2011).


INTRODUCTION Since the first biological factor that neutralized tumor necrosis (TNF)-α was brought to the market, there has been a desperate search for small molecules with the same efficacy in therapy of inflammatory disorders. One of the most promising targets is p38α mitogen-activated protein (MAP) kinase. This enzyme is a key player in a vast number of… (More)
DOI: 10.1517/13543776.2011.636737


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.